SEARCH

SEARCH BY CITATION

References

  • 1
    Ruggeri ZM. Platelets in atherothrombosis. Nat Med 2002; 8: 122734.
  • 2
    Trip MD, Cats VM, Van Capelle FJ, Vreeken J. Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990; 322: 154954.
  • 3
    Kabbani SS, Watkins MW, Ashikaga T, Terrien EF, Holoch PA, Sobel BE, Schneider DJ. Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention. Circulation 2001; 104: 1816.
  • 4
    Kabbani SS, Watkins MW, Ashikaga T, Terrien EF, Sobel BE, Schneider DJ. Usefulness of platelet reactivity before percutaneous coronary intervention in determining cardiac risk one year later. Am J Cardiol 2003; 91: 8768.
  • 5
    Tschoepe D, Schultheiss HP, Kolarov P, Schwippert B, Dannehl K, Nieuwenhuis HK, Kehrel B, Strauer B, Gries FA. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation 1993; 88: 3742.
  • 6
    Thaulow E, Erikssen J, Sandvik L, Stormorken H, Cohn PF. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men. Circulation 1991; 84: 6137.
  • 7
    Frossard M, Fuchs I, Leitner JM, Hsieh K, Vlcek M, Losert H, Domanovits H, Schreiber W, Laggner AN, Jilma B. Platelet function predicts myocardial damage in patients with acute myocardial infarction. Circulation 2004; 110: 13927.
  • 8
    Refaai MA, Laposata M. Platelet aggregation. In: MichelsonAD, ed. Platelets. San Diego: Academic Press, 2002: 2916.
  • 9
    Michelson AD. Platelet function testing in cardiovascular diseases. Circulation 2004; 110: e489e93.
  • 10
    Yee DL, Sun CW, Bergeron AL, Dong JF, Bray PF. Aggregometry detects platelet hyperreactivity in healthy individuals. Blood 2005; 106: 27239.
  • 11
    Zhang JN, Bergeron AL, Yu Q, Sun C, McIntire LV, Lopez JA, Dong JF. Platelet aggregation and activation under complex patterns of shear stress. Thromb Haemost 2002; 88: 81721.
  • 12
    Weiss HJ, Sussman II. A new von Willebrand variant (type I, New York): increased ristocetin-induced platelet aggregation and plasma von Willebrand factor containing the full range of multimers. Blood 1986; 68: 14956.
  • 13
    Stenberg PE, McEver RP, Shuman MA, Jacques YV, Bainton DF. A platelet alpha-granule membrane protein (GMP-140) is expressed on the plasma membrane after activation. J Cell Biol 1985; 101: 8806.
  • 14
    Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998; 94: 65766.
  • 15
    Motulsky HJ, Shattil SJ, Insel PA. Characterization of alpha 2-adrenergic receptors on human platelets using [3H]yohimbine. Biochem Biophys Res Commun 1980; 97: 156270.
  • 16
    Hoffman BB, Michel T, Brenneman TB, Lefkowitz RJ. Interactions of agonists with platelet alpha 2-adrenergic receptors. Endocrinology 1982; 110: 92632.
  • 17
    Freeman K, Farrow S, Schmaier A, Freedman R, Schork T, Lockette W. Genetic polymorphism of the alpha 2-adrenergic receptor is associated with increased platelet aggregation, baroreceptor sensitivity, and salt excretion in normotensive humans. Am J Hypertens 1995; 8: 8639.
  • 18
    Lanza F, Beretz A, Stierle A, Hanau D, Kubina M, Cazenave JP. Epinephrine potentiates human platelet activation but is not an aggregating agent. Am J Physiol 1988; 255: H1276H88.
  • 19
    Rao GH, White JG. Epinephrine and platelet function. J Lab Clin Med 1997; 130: 2389.
  • 20
    Woulfe DS. Platelet G protein-coupled receptors in hemostasis and thrombosis. J Thromb Haemost 2005; 3: 2193200.
  • 21
    Simonds WF, Goldsmith PK, Codina J, Unson CG, Spiegel AM. Gi2 mediates alpha 2-adrenergic inhibition of adenylyl cyclase in platelet membranes: in situ identification with G alpha C-terminal antibodies. Proc Natl Acad Sci USA 1989; 86: 780913.
  • 22
    Richardson M, Robishaw JD. The alpha2A-adrenergic receptor discriminates between Gi heterotrimers of different betagamma subunit composition in Sf9 insect cell membranes. J Biol Chem 1999; 274: 1352533.
  • 23
    Siffert W, Rosskopf D, Siffert G, Busch S, Moritz A, Erbel R, Sharma AM, Ritz E, Wichmann HE, Jakobs KH, Horsthemke B. Association of a human G-protein beta3 subunit variant with hypertension. Nat Genet 1998; 18: 458.
  • 24
    Siffert W. G protein polymorphisms in hypertension, atherosclerosis, and diabetes. Annu Rev Med 2005; 56: 1728.
  • 25
    Naber C, Hermann BL, Vietzke D, Altmann C, Haude M, Mann K, Rosskopf D, Siffert W. Enhanced epinephrine-induced platelet aggregation in individuals carrying the G protein beta3 subunit 825T allele. FEBS Lett 2000; 484: 199201.
  • 26
    Frey UH, Aral N, Muller N, Siffert W. Cooperative effect of GNB3 825C > T and GPIIIa PI(A) polymorphisms in enhanced platelet aggregation. Thromb Res 2003; 109: 27986.
  • 27
    O'Donnell CJ, Larson MG, Feng D, Sutherland PA, Lindpaintner K, Myers RH, D'Agostino RA, Levy D, Tofler GH. Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 2001; 103: 30516.
  • 28
    Pasha R, Benavides M, Kottke-Marchant K, Harasaki H. Reduced expression of platelet surface glycoprotein receptor IIb/IIIa at hyperthermic temperatures. Lab Invest 1995; 73: 4038.
  • 29
    Hetherington SL, Singh RK, Lodwick D, Thompson JR, Goodall AH, Samani NJ. Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP. Arterioscler Thromb Vasc Biol 2005; 25: 2527.
  • 30
    Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet 1991; 338: 140911.
  • 31
    Endler G, Klimesch A, Sunder-Plassmann H, Schillinger M, Exner M, Mannhalter C, Jordanova N, Christ G, Thalhammer R, Huber K, Sunder-Plassmann R. Mean platelet volume is an independent risk factor for myocardial infarction but not for coronary artery disease. Br J Haematol 2002; 117: 399404.
  • 32
    Burger PC, Wagner DD. Platelet P-selectin facilitates atherosclerotic lesion development. Blood 2003; 101: 26616.
  • 33
    Huo Y, Schober A, Forlow SB, Smith DF, Hyman MC, Jung S, Littman DR, Weber C, Ley K. Circulating activated platelets exacerbate atherosclerosis in mice deficient in apolipoprotein E. Nat Med 2003; 9: 617.
  • 34
    Dole VS, Bergmeier W, Mitchell HA, Eichenberger SC, Wagner DD. Activated platelets induce Weibel-Palade-body secretion and leukocyte rolling in vivo: role of P-selectin. Blood 2005; 106: 23349.